WO2015148648A1 - Formulation d'adjuvant non toxique comprenant une composition de liposomes contenant un lipide a monophosphorylé (mpla) et une saponine - Google Patents
Formulation d'adjuvant non toxique comprenant une composition de liposomes contenant un lipide a monophosphorylé (mpla) et une saponine Download PDFInfo
- Publication number
- WO2015148648A1 WO2015148648A1 PCT/US2015/022461 US2015022461W WO2015148648A1 WO 2015148648 A1 WO2015148648 A1 WO 2015148648A1 US 2015022461 W US2015022461 W US 2015022461W WO 2015148648 A1 WO2015148648 A1 WO 2015148648A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- less
- mol
- mpla
- adjuvant formulation
- saponin
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 153
- 239000000203 mixture Substances 0.000 title claims abstract description 133
- 229940035032 monophosphoryl lipid a Drugs 0.000 title claims abstract description 119
- 238000009472 formulation Methods 0.000 title claims abstract description 63
- 239000002671 adjuvant Substances 0.000 title claims abstract description 52
- 150000007949 saponins Chemical class 0.000 title claims abstract description 41
- 229930182490 saponin Natural products 0.000 title claims abstract description 40
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 35
- 231100000252 nontoxic Toxicity 0.000 title description 2
- 230000003000 nontoxic effect Effects 0.000 title description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 64
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 46
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 32
- 239000000232 Lipid Bilayer Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000008018 melting Effects 0.000 claims abstract description 9
- 238000002844 melting Methods 0.000 claims abstract description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 8
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 34
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 34
- 230000002163 immunogen Effects 0.000 claims description 26
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims description 25
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims description 25
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 20
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 19
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 14
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 13
- HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000002691 unilamellar liposome Substances 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract description 21
- -1 QS-21) Chemical class 0.000 abstract description 9
- 231100000324 minimal toxicity Toxicity 0.000 abstract description 2
- 235000017709 saponins Nutrition 0.000 description 29
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 18
- 239000012480 LAL reagent Substances 0.000 description 17
- 239000002158 endotoxin Substances 0.000 description 17
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- 206010018910 Haemolysis Diseases 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000008588 hemolysis Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000002949 hemolytic effect Effects 0.000 description 12
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000004990 Smectic liquid crystal Substances 0.000 description 5
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241000714177 Murine leukemia virus Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000004973 liquid crystal related substance Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 238000011050 LAL assay Methods 0.000 description 2
- 241000239218 Limulus Species 0.000 description 2
- 241000239220 Limulus polyphemus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- 241001454523 Quillaja saponaria Species 0.000 description 2
- 235000009001 Quillaja saponaria Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003012 bilayer membrane Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000020030 perry Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- PIGTXFOGKFOFTO-PPEDVFHSSA-N CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@@](C)(C=O)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O Chemical compound CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@@](C)(C=O)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O PIGTXFOGKFOFTO-PPEDVFHSSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241001441550 Zeiformes Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- YMJBYRVFGYXULK-QZABAPFNSA-N alpha-D-glucosamine 1-phosphate Chemical group N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(O)=O YMJBYRVFGYXULK-QZABAPFNSA-N 0.000 description 1
- 229920006187 aquazol Polymers 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229940052961 longrange Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
Definitions
- compositions comprising a monophosphoryl lipid A (MPLA)-containing liposome and at least one saponin, e.g., QS-21.
- the liposome comprises i) a lipid bilayer comprising phospholipids in which the hydrocarbon chains have a melting temperature in water of > 23 °C and ii) cholesterol at a mole percent concentration of greater than about 50% (mol/mol).
- LPS Lipopolysaccharides
- lipid A which is the innermost region of LPS that serves as the hydrophobic anchor and comprises phosphorylated glucosamine disaccharide units carrying long chain fatty acids.
- LPS lethal toxicity, pyrogenicity, and adjuvanticity
- lipid A moiety of lipid A
- Both LPS and lipid A have long been known for their strong adjuvant effects, but the high toxicity of these molecules has limited their use in vaccine formulations.
- Significant scientific effort has occurred towards reducing the toxicity of LPS or lipid A while maintaining their adjuvanticity.
- Quillaja saponins are a mixture of amphipathic triterpene glycosides extracted from the bark of the tree Quillaja saponaria. Crude saponins have been employed as veterinary adjuvants.
- Quil-A is a partially purified aqueous extract of the Quillaja saponin material
- QS-21 is an HPLC purified fraction of Quil A. Methods of producing QS-21 (referred to as QA21 ) are disclosed in U.S. Pat. No. 5,057,540.
- One of the major side effects of using saponins such as QS-21 is its cytotoxicity. Specifically, although the exact cytotoxic mechanism is currently unknown, saponins cause hemolysis, which is the rupturing or lysis of red blood cells.
- an adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)) composition and a saponin, wherein the adjuvant formulation displays minimal toxicity of either lipid A or saponin.
- MPLA monophosphoryl lipid A
- L(MPLA) monophosphoryl lipid A
- an adjuvant formulation comprising a
- the liposome composition comprises i) a lipid bilayer composing phospholipids in which the hydrocarbon chains have a melting temperature in water of > 23°C and ii) cholesterol at a mole percent concentration of greater than about 50% (mol/mol).
- the saponin may be selected from QS-7, QS- 18, QS-21 , or a mixture thereof.
- the saponin can be QS-21 .
- the liposome composition of the adjuvant formulation may comprise cholesterol at a mole percent concentration of about 55% to about 71% (mol/mol), or preferably about 55% (mol/mol).
- the liposome composition of the adjuvant formulation may comprise a phosphatidylcholine (PC) selected from the group consisting of: dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), and distearyl phosphatidylcholine (DSPC).
- PC phosphatidylcholine
- DMPC dimyristoyl phosphatidylcholine
- DPPC dipalmitoyl phosphatidylcholine
- DSPC distearyl phosphatidylcholine
- the liposome composition of the adjuvant formulation may comprise multi-lamellar vesicles (MLV) or small uni-lamellar vesicles (SUV), wherein small uni-lamellar vesicles are about 50 to about 100 nra in diameter, and wherein multi-lamellar vesicles are about 1 to about 4 ⁇ in diameter.
- MLV multi-lamellar vesicles
- SUV small uni-lamellar vesicles
- the liposome composition of the adjuvant formulation may comprise about 5 mg or less, about 4 mg or less, about 3 mg or less, about 2 mg or less, about 1 mg or less, about 0.9 mg or less, about 0.8 mg or less, about 0.7 mg or less, about 0.6 mg or less, about 0.5 mg or less, about 0.4 mg or less, about 0.3 mg or less, about 0.2 mg or less, about 0.1 mg or less, about 0.09 mg or less, about 0.08 mg or less, about 0.07 mg or less, about 0.06 mg or less, about 0.05 mg or less, about 0.04 mg or less, about 0.03 mg or less, about 0.02 mg or less, or about 0.01 mg or less of MPLA (total weight per ml liposome suspension).
- the liposome composition of the adjuvant formulation may have a MPLA:phospholipid mole ratio of about 1 :5.6 to about 1 :880, or about 1 :88 to about 1 :220.
- a method of reducing toxicity of a saponin as an adjuvant or preparing an adjuvant formulation comprising adding a monophosphoryl lipid A (MPLA)-containing liposome composition to the saponin, wherein the liposome composition comprises i) a lipid bilayer comprising phospholipids in which the hydrocarbon chains have a melting temperature in water of > 23°C and ii) cholesterol at a mole percent concentration of greater than about 50% (mol/mol).
- the saponin may be selected from the group consisting of QS-7, QS- 1 8, QS-21 , and a mixture thereof.
- saponin can be QS-21 .
- the liposome composition may comprise cholesterol at a mole percent concentration of about 55% to about 71 % (mol/mol), preferably, about 55% (mol/mol).
- FIG. 1 depicts hemolytic activities of liposome compositions with various QS-21 concentrations (FIG. 1 A: 10 ⁇ QS-21 ; FIG. I B: 50 ng/ml QS-21 ) as described in Example 1 .
- FIG. 2 depicts hemolysis of erythrocytes by QS-21 pre-incubated with liposomes as described in Example 1 .
- QS-21 was mixed with DMPC/DMPG liposomes containing a total of 5 ⁇ of phospholipids at 22 °C.
- the liposomes also contained 33.7, 43 , or 55 mol% Choi .
- FIG. 4 depicts inhibition of binding of QS-21 to liposomal Choi by liposomal MPLA.
- the experiments were conducted as described in Example 2.
- the mean ⁇ S.D. is shown with 14 independent liposome batches of L, and with 4 independent batches of L(MPLA).
- FIG. 5 depicts effect of phospholipid fatty acyl chain length on accessibility of liposomal Choi for binding of QS-21 .
- the experiments were conducted as described in Example 2.
- FIG. 5A illustrates the results of the liposomes with 33.7 mol% Choi and no MPLA.
- FIG. 5B illustrates the results of the liposomes with 55 mol% Choi, and no MPLA.
- FIG. 5C illustrates the results of the liposomes with 55 mol% Choi and MPLA.
- FIG. 7 depicts suppression of LAL positivity of DMPC/DMPG/Chol/MPLA liposome by increasing liposomal Choi contents. Results of LAL binding to liposomes containing 33.7 mol% Choi are shown in FIG. 7A, while results of LAL binding to liposomes containing 55 mol% Choi are shown in FIG. 7B.
- MPLA phospholipid ratios of 1 :88 or 1 :5.6.
- the curves represent ALFQ in which the initial ALF comprised (from left to right): MLV with MPLA.phospholipid ratio of 1 :220; and SUV with
- MPLA phospholipid ratios of 1 :88 and 1 :5.6, respectively.
- FIG. 9 depicts IgG endpoint titers to gp l40.
- Mice were immunized with ALF+CN gp l 40 (FIG. 9A) and ALFQ+CN gp l40 (FIG. 9B) containing the indicated MPLA:phospholipid molar ratios in which 20 ⁇ g of MPLA was present in each formulation.
- Sera were from week 9 and were assayed by ELISA. Values are the mean of 6 animals/group ⁇ standard deviation.
- F G. 10 depicts IgG subtype profiles of anti-gp l 40 antisera as described in Example 4 and Materials and Methods. Mice were immunized with ALF+gp l 40 (FIG. 10A) or ALFQ+gp l 40 (FIG. 10B). ELISA plates were coated with gpl 40. Subtype analyses were conducted and values were calculated from standard curves. Each panel represents pooled sera from one group from week 9 of immunized mice.
- FIG. 1 1 depicts production of IFN- ⁇ (FIG. 1 1A) and IL-4 (FIG. 1 IB) by splenocytes from mice 9 weeks after primary immunization.
- Splenocytes were plated and stimulated with gpl40 CN54 for 18 hours, and the number of cytokine producing cells were determine by ELISPOT.
- Vertical lines represent the mean of the 6 animals/group (Na ' ive: non-immunized control mice).
- FIG. 12 depicts neutralization of HIV by pooled antisera.
- the vaccine formulation is indicated on the x-axis.
- ID50 values represent 50% neutralization of pseudoviruses MW965.26PV (FIG. 12A) and GS015PV (FIG. 12B) at the indicated dilution of the serum samples from mice 9 weeks after primaiy immunization.
- the controls were sera from non-immunized mice.
- ID50 values ⁇ 20 were considered as background. MuLV PV was used as assay negative control (data not shown).
- immunogen is an agent capable of inducing humoral and/or cell- mediated immune response.
- the immunogen as described herein can be an antigen, a hapten, or an inactivated pathogen.
- An immunogenic composition as described herein can be, for example, a vaccine formulation.
- Liposomes refer to closed bilayer membranes containing an entrapped aqueous volume. Liposomes may also be uni-lamellar vesicles possessing a single membrane bilayer or multi-lamellar vesicles with multiple membrane bilayers, each separated from the next by an aqueous layer. The structure of the resulting membrane bilayer is such that the hydrophobic (non-polar) tails of the lipid are oriented toward the center of the bilayer while the hydrophilic (polar) heads orient towards the aqueous phase.
- Liposomes as they are ordinarily used, consist of smectic mesophases, and can consist of either phospholipid or nonphospholipid smectic mesophases. Smectic mesophase is most accurately described by Small, HANDBOOK OF LIPID RESEARCH, Vol. 4, Plenum, NY, 1986, pp. 49-50. According to Small, "[w]hen a given molecule is heated, instead of melting directly into an isotropic liquid, it may instead pass through intermediate states called mesophases or liquid crystals, characterized by residual order in some directions but by lack of order in others ... In general, the molecules of liquid crystals are somewhat longer than they are wide and have a polar or aromatic part somewhere along the length of the molecule.
- the molecular shape and the polar-polar, or aromatic, interaction permit the molecules to align in partially ordered arrays ... These structures characteristically occur in molecules that possess a polar group at one end.
- Liquid crystals with long- range order in the direction of the long axis of the molecule are called smectic, layered, or lamellar liquid crystals ... In the smectic states the molecules may be in single or double layers, normal or tilted to the plane of the layer, and with frozen or melted aliphatic chains.”
- Lipid A is a set of complex, heavily acylated and amidated diglucosamine diphosphate molecules and is the lipid moiety common to all lipopolysaccharides (LPS; also known as endotoxin) from Gram-negative bacteria.
- LPS lipopolysaccharides
- LPS covers virtually the entire outer surface of all Gram-negative bacteria, and lipid A anchors the LPS into the outer lipid surface of the bacterium.
- the O-polysaccharide portion of LPS in wild-type smooth bacteria is linked to a relatively conserved core oligosaccharide that is expressed in rough mutants, and this in turn is linked to lipid A through highly conserved 2-keto-3-deoxyoctanoic acid sugars that are unique chemical structures sometimes required for bacterial viability and found only in LPS.
- “Monophosphoryl lipid A” is a lipid A congener in which the glucosamine- 1 -phosphate group on the polar head group has been removed. Numerous congeners of MPLA also exist.
- the "mole percent concentration of cholesterol" of a liposome composition as used herein refers to the ratio of Choktotal phospholipid (i.e., phosphatidylcholine and phosphatidylglycerol) originally used in the preparation of the liposome composition.
- a “physiologically acceptable vehicle” as used herein refers to a vehicle that is suitable for in vivo administration (e.g., oral, transdermal or parenteral administration) or in vitro use, i.e., cell culture.
- exemplary physiologically acceptable vehicles can be those physiologically acceptable constituents of liposomes as disclosed in U.S. Patent Nos. 4,186, 183 and 4,302,459.
- a suitable saponin is Quil A, its derivatives thereof, or any purified component thereof (for example, QS-7, QS- 18, QS-21 , or a mixture thereof).
- Quil A is a saponin preparation isolated from the South American tree Quillaja Saponaria Molina and was first found to have adjuvant activity.
- Liposomes are closed bilayer membranes containing an entrapped aqueous volume. Liposomes may also be uni-lamellar vesicles possessing a single membrane bilayer or multi-lamellar vesicles with multiple membrane bilayers, each separated from the next by an aqueous layer.
- the structure of the resulting membrane bilayer is such that the hydrophobic (non-polar) tails of the lipid are oriented toward the center of the bilayer while the hydrophilic (polar) heads orient towards the aqueous phase.
- Suitable hydrophilic polymers for surrounding the liposomes include, without limitation, PEG, polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline,
- Liposomes can be made without hydrophilic polymers. Therefore, liposome formulations may or may not contain hydrophilic polymers.
- Liposomes may be comprised of any lipid or lipid combination known in the art.
- the vesicle-forming lipids may be naturally-occurring or synthetic lipids, including phospholipids, such as phosphatidylcholine,
- MPLA serves as a potent adjuvant and serves to raise the immunogenicity of the liposome and peptides, proteins, or haptens associated with the liposome.
- a typical monophosphoryl lipid A (MPLA)- containing liposome (L(MPLA)) is the one originally referred to as Walter Reed liposomes but now known as Army Liposome Formulation (ALF), as a vaccine adjuvant.
- MPLA monophosphoryl lipid A
- ALF Army Liposome Formulation
- an L(MPLA) may comprise a
- PC phosphatidylcholine
- DMPC dimyristoyl phosphatidylcholine
- DPPC dipalmitoyi phosphatidylcholine
- DSPC disteaiyl phosphatidylcholine
- the L(MPLA) may also comprise a
- Adjuvant formulations comprising liposome and saponin
- the AS01 formulation is being developed as an adjuvant for a variety of vaccines. See Garcon & Mechelen, 201 1 , Expert. Rev. Vaccines, 10: 471-86.
- the AS01 formulation as described in U.S. Published Patent Application No. 201 1/0206758, may contain cholesterol (sterol) at a mole percent concentration of 1 -50% (mol/mol), preferably 20-25% (mol/mol).
- the adjuvant formulation comprises
- the saponin may be selected from QS-7, QS-18, QS-21 , or a mixture thereof, or the saponin preferably may be QS-21.
- the adjuvant formulation may contain about 1 mg or less, about 0.9 mg or less, about 0.8 mg or less, about 0.7 mg or less, about 0.6 mg or less, about 0.5 mg or less, about 0.4 mg or less, about 0.3 mg or less, about 0.2 mg or less, about 0.1 mg or less, about 0.09 mg or less, about 0.08 mg or less, about 0.07 mg or less, about 0.06 mg or less, about 0.05 mg or less, about 0.04 mg or less, about 0.03 mg or less, about 0.02 mg or less, or about 0.01 mg or less of saponin per ml liposome suspension.
- DMEM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- penicillin 100 unit/ml penicillin
- streptomycin 100 g/ml streptomycin
- 2 niM L-glutamine was used for culturing TZM.bl cells and for HlV- 1 neutralization assays.
- Liposomal Choi concentration was 43 mol% in all ALF preparations lacking QS-21.
- Liposomes were microfluidized using a Microfluidics LV 1 low volume high shear microfluidizer (ATS Scientific Inc., Burlington, Ontario, Canada) at 30,000 psi to form SUVs.
- the diameter size distributions of liposomes were measured by Horiba LB-550 particle sizer (Horiba Scientific, New Jersey, NJ).
- Army liposome formulations plus QS-21 (ALFQ) were made by mixing MLV or SUV liposomes in which the Choi concentration was 55 mol% with QS-21 .
- the QS-2 1 irreversibly binds to the Choi in the liposomes under these conditions with no detectable free QS- 21 present in the buffer.
- the total amount of QS-21 in each ALFQ formulation used for immunization was 10 ⁇ g.
- Cholesterol content was analyzed to confirm the cholesterol, and indirectly, the phospholipid concentration of the liposome formulations by the established methods. See, e.g. , Zlatkis et al., 1953, J. Lab. Clin. Med. , 41 : 486-492. Briefly, 5 to 200 ⁇ of liposomes were added to water to a final volume of 200 ⁇ . Three ml of glacial acetic acid were added, followed by the addition of 2 ml of 0.1 % ferric chloride in glacial sulfuric acid. After mixing and then equilibrating, the samples to room temperature, absorbance was read at 560 ran. The cholesterol concentration of the liposomes was determined from a cholesterol standard curve.
- red blood cells Hemolysis of red blood cells was used as a measure both of the relative amount of free QS-21 , and of the toxicity of QS-21 under the indicated experimental conditions.
- Human red blood cells were purchased from the Research Blood
- Limulus amebocyte lysate (LAL) assay was used as a probe to examine the roles of phospholipid chain length and mole fraction of Choi on the liposomal surface expression of MPLA.
- a lysate of amebocytes from the blood of Limulus polyphemus (Atlantic horseshoe crab) containing a clotting protein is widely used as a surrogate probe for detecting the endotoxic activity of LPS or lipid A. See, e.g. , Brandenburg et al., 2009, Curr. Med. Chem., 16: 2653-2660.
- mice Female Balb/c mice (Charles River Laboratories, Indianapolis, IN, USA) (5-6 weeks of age; 6/group) were immunized intramuscularly (IM) with 0.05 ml of the vaccines by injection in alternative rear thighs at 0, 3 and 6 weeks.
- IM intramuscularly
- Four mouse groups were immunized with the ALF+gp l 40 formulations listed above and three groups were immunized with the ALFQ+gp MO formulations.
- One mouse group was not immunized, and was used as negative control for the immunological studies.
- the animals were bled prior to the first immunization and 3 and 6 weeks after the primary immunization. At week 9, the animals were terminally bled and the spleens were collected.
- HRP-linked sheep anti-mouse IgG (0.1 ⁇ g in 100 ⁇ blocking buffer) was added to each well and plates were incubated for 1 hour followed by washing.
- One hundred ⁇ of ABTS 2-component substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) were added to each well, and plates were incubated for 1 hour. Color development was stopped by adding 100 ⁇ /well of 1 % SDS. The absorbance was read at 405 nm. End point titer was defined as the dilution at which the absorbance was twice background.
- IgG subtype determination was modified from Glenn et al., 1995, Immunol. Let. 47: 73-78.
- a standard curve was made by using unconjugated goat anti-mouse IgG (Fab).
- Fab unconjugated goat anti-mouse IgG
- One hundred ⁇ of Fab 1 ⁇ g ml in PBS was added to the wells of 96-well Immulon 2HB flat bottom plates and the plates were incubated overnight at 4°C. Plates were washed 3 times with 0.05%) Tween 20 in PBS (washing buffer), blocked with 250 ⁇ /well of 0.5%> skim milk in PBS (blocking buffer), and incubated at room temperature (RT) for 1 hour. After washing, 100 ⁇ of blocking buffer were added to each well.
- Purified mouse IgG 1 , lgG2a, IgG2b, and IgG3 were diluted two-fold starting from 200 ng/ml of blocking buffer. One hundred ⁇ of each dilution were added to the plates. Plates were incubated at room temperature for 2 hours, and washed 3 times. One hundred ⁇ of HRP-linked goat anti-mouse IgG l , IgG2a, IgG2b, and IgG3 ( 1 : 1000 dilution in blocking buffer) were added to the corresponding wells, and plates were incubated at room temperature for 1 hour. Plates were washed and 100 ⁇ of ABTS were added. Color development was stopped with 100 ⁇ /well of 1% SDS.
- Spleens from euthanized mice were pressed through a 100- ⁇ nylon cell strainer (Thomas Scientific, Swedesboro, NJ, USA, cat No. 4620F05) with the plunger of a syringe. Splenic cell suspensions were collected in and washed 3 times with cRPMI medium. ELISPOT was conducted as described in Rao et al., 2002, J. Virol, 76: 9176-85.
- multiScreen 96-well microtiter plates Prior to the harvesting of spleens, multiScreen 96-well microtiter plates (EMD Millipore, Billerica, MA, USA) were pre-treated with 70% ethanol, washed 3 times with PBS and coated with 100 ⁇ /well of either 5 ⁇ g/ml of capture INF-y-specific IgG diluted in PBS or 2 igl ⁇ of capture IL-4-specific specific IgG diluted in PBS. Plates were incubated overnight at 4°C, then washed 2 times with cRPMI and blocked with 200 ⁇ /well cRMPl at RT for 2 hours. Fifty ⁇ of mouse cell suspensions (8 x 10 6 cells/ml) were plated in duplicate for each cytokine assay.
- Neutralizing antibody responses against two tier 1 HIV- 1 Env pseudoviruses were measured by using luciferase-based virus neutralization assays with TZM.bl cells as previously described. See, e.g. , Brown et al., 2007, J. Virol , 81 : 2087-91.
- the 50% inhibitory dilution of serum (ID50) was calculated as the serum dilution that resulted in a 50% reduction in relative luminescence units compared with the virus control wells after the subtraction of cell control relative luminescence units.
- DMEM Dulbecco's modified Eagle's medium
- HIV clade C, GS015 PV and MW965.26 PV (25 ⁇ ) were added to each well and the plates were incubated for 1 h at 37°C.
- TZM.bl cells were then added ( 104 cells/well) in a 50 ⁇ volume in 1 0% DMEM containing DEAE-dextran, and neutralizing antibody titers were determined as previously described in Brown et al., 2008.
- Murine leukemia virus (MuLV) negative controls were included in all assays.
- the hemolytic activities of liposome compositions with QS-21 were characterized first by varying QS-21 concentration. Briefly, fifty millimolar phospholipid liposomes containing 33.7%, 43%, and 55% cholesterol were mixed and incubated with 1 0 ⁇ g/m l and 50 pg/ml QS-21 at room temperature for 20 minutes. Red blood cells were added to the mixture of liposome-QS-21 , and incubated for 30 minutes. Free QS-21 served as positive control. Cells were centrifuged and the optical density of supernatant was measured at 541 nm to reflect the levels of hemolysis. The results, as presented in FIG. 1 , suggest that the levels of hemolysis by liposome compositions with QS-21 depends upon the concentration of cholesterol in the liposomes.
- the hemolytic activities of liposome compositions with QS-21 were further characterized by varying mol% of liposomal Choi.
- the degree of eiythrocyte damage caused by QS-21 was found to be inversely related to the mol% of liposomal Choi that had been pre-incubated with QS-21 (FIG. 2). While free QS-21 caused maximum hemolysis at approximately 2 ⁇ g, maximum hemolysis occurred at approximately 4 ⁇ g of QS-21 when QS-21 was pre-incubated with liposomes containing either 33.7 or 43 mol% Choi (FIG. 2). Liposomes having 55 mol% Choi completely blocked the hemolytic effect of QS-21 up to 200 ⁇ g (FIG. 2). Similar results were observed for liposome compositions containing varying concentrations of saponin (FIG. 3). No hemolysis with up to 500 ⁇ g/ml saponins was detected when liposomes contained 55 mol% cholesterol.
- LAL Limulus amebocyte lysate
- FIG. 7A shows that the MPLA in DMPC/DMPC/Chol/MPLA, DPPC/DMPC/Chol/MPLA, or DSPC/DMPC/Chol/MPLA liposomes containing 33.7 mol % Choi was detected by the LAL assay.
- the recognition of MPLA by LAL in liposomes containing 33.7% Choi was proportional to the length of saturated fatty acyl chains of phosphatidylcholine, with LAL binding in the order DSPC > DPPC > DMPC.
- MLV and SUV each being a type of ALF liposomes (i.e., containing MPLA), were constructed.
- ALF MLV was between 1 and 4 ⁇ .
- MLV indicates that light scattering analysis detected many large particles
- MLV also contains numerous small particles in a hyperbolic distribution as shown by electronic particle size analysis. See, e.g. , Alving et al., 1975, Biochim. Biophys. Acta., 394: 157-65.
- FIG. 9A ALF SUV containing MPLA:phospholipid in the ratio of 1 :88 induced higher IgG anti-gpl40 binding antibody production in mice than ALF MLV having the same MPLA:phospholipid ratio in a statistically significant fashion.
- ALF SUV with an MPLA:phospholipid ratio of 1 :5.6 induced the highest titer of binding antibodies.
- FIG. 9B shows that all ALFQ-adjuvanted formulations induced significantly higher binding antibodies to gpl40 than any of the ALF MLV- adjuvanted formulations. The total gpl40-specific IgG binding antibody levels in all ALFQ-adjuvanted groups appeared independent of the size of the liposomes or the relative phospholipid concentration.
- IgG subtype determination was conducted to further characterize the antibody production. All mouse groups immunized with ALF + gpl40 revealed moderate or high titers of IgG 1 binding antibodies to gpHO (FIG. 10A). ALF MLV induced dominantly IgGl subclass, while ALF SUV induced a balance between IgGl and IgG2a production and also induced IgG2b production. Increasing the expression
- FIG. 10A As shown in FIG. 10B, in the ALFQ groups the serum concentration of IgGl was constantly high; and all subtypes were induced, but these were independent of the MPLAiphospholipid ratios of ALF SUV or ALF MLV initially utilized for creation of ALFQ.
- ELISPOT analyses were performed on freshly isolated splenic lymphocytes from mice immunized with adjuvanted gpl40. As shown in FIG. 1 1, all of the ALF-adjuvanted formulations induced proliferation of I F-y-producing splenic lymphocytes that was higher than observed with the na ' fve control. ALFQ formulations induced significantly higher numbers of INF-y-positive cells than ALF (FIG. 1 1A). All of the immunized mice exhibited high IL-4 production that was significantly higher (p ⁇ 0.0001) than naive mice (FIG. 1 IB). Significant differences of IL-4 producing cell numbers were not observed among immunized groups.
- the ALFQ liposomes caused a distinctive induction of INF- ⁇ secretion that was independent of the MPLA:phospholipid ratio.
- the ALFQ liposomes might be a potentially useful adjuvant for induction of Thl -type immunity.
- ALF having MPLA:phospholipid ratio of 1 :5.6 induced the highest neutralization titer, while ALFQ with 1 :88 and 1 :220 MPLA:phospholipid ratios also induced neutralizing antibodies, but with somewhat lower titers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15716264.5A EP3122380A1 (fr) | 2014-03-25 | 2015-03-25 | Formulation d'adjuvant non toxique comprenant une composition de liposomes contenant un lipide a monophosphorylé (mpla) et une saponine |
JP2017502920A JP6608422B2 (ja) | 2014-03-25 | 2015-03-25 | モノホスホリルリピッドa(mpla)含有リポソーム組成物およびサポニンを含む非毒性アジュバント製剤 |
AU2015236106A AU2015236106A1 (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (MPLA)-containing liposome composition and a saponin |
RU2016141622A RU2016141622A (ru) | 2014-03-25 | 2015-03-25 | Нетоксичный адъювантный состав, содержащий композицию содержащей монофосфорил-липид а (mpla) липосомы и сапонин |
CA2943190A CA2943190A1 (fr) | 2014-03-25 | 2015-03-25 | Formulation d'adjuvant non toxique comprenant une composition de liposomes contenant un lipide a monophosphoryle (mpla) et une saponine |
MX2016012168A MX2016012168A (es) | 2014-03-25 | 2015-03-25 | Formulacion adyuvante no toxica que comprende una composicion de liposoma que contiene monofosforil-lipido a (mpla) y una saponina. |
KR1020167026025A KR102242875B1 (ko) | 2014-03-25 | 2015-03-25 | 모노포스포릴 지질 a (mpla)-함유 리포솜 조성물 및 사포닌을 포함하는 무독성 아주반트 제제 |
SG11201607396WA SG11201607396WA (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin |
US15/127,081 US10434167B2 (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin |
CN201580026334.9A CN107124869B (zh) | 2014-03-25 | 2015-03-25 | 包含含有单磷酰脂质a(mpla)的脂质体组合物和皂苷的无毒佐剂制剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461970118P | 2014-03-25 | 2014-03-25 | |
US61/970,118 | 2014-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015148648A1 true WO2015148648A1 (fr) | 2015-10-01 |
Family
ID=52829375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/022461 WO2015148648A1 (fr) | 2014-03-25 | 2015-03-25 | Formulation d'adjuvant non toxique comprenant une composition de liposomes contenant un lipide a monophosphorylé (mpla) et une saponine |
Country Status (11)
Country | Link |
---|---|
US (1) | US10434167B2 (fr) |
EP (1) | EP3122380A1 (fr) |
JP (1) | JP6608422B2 (fr) |
KR (1) | KR102242875B1 (fr) |
CN (1) | CN107124869B (fr) |
AU (1) | AU2015236106A1 (fr) |
CA (1) | CA2943190A1 (fr) |
MX (1) | MX2016012168A (fr) |
RU (1) | RU2016141622A (fr) |
SG (2) | SG11201607396WA (fr) |
WO (1) | WO2015148648A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017153993A1 (fr) * | 2016-03-09 | 2017-09-14 | Technion Research And Development Foundation Ltd. | Formulations liposomales et leurs procédés d'utilisation en agriculture |
WO2019051149A1 (fr) * | 2017-09-08 | 2019-03-14 | Infectious Disease Research Institute | Formulations liposomales comprenant de la saponine et procédés d'utilisation |
EP3615005A4 (fr) * | 2017-04-28 | 2021-03-10 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Compositions et méthodes d'administration de vaccins |
WO2023175454A1 (fr) | 2022-03-14 | 2023-09-21 | Pfizer Inc. | Procédés de production d'adjuvant |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6661454B2 (ja) * | 2016-04-21 | 2020-03-11 | 株式会社東海理化電機製作所 | 表示装置、表示板の製造方法 |
CN107669692B (zh) * | 2017-09-07 | 2020-09-29 | 中国人民解放军第二军医大学 | Mpla在制备电离辐射致肠道损伤防治药物中的应用 |
WO2020243166A1 (fr) * | 2019-05-28 | 2020-12-03 | The Regents Of The University Of California | Adjuvants de polarisation th1 pour améliorer l'immunogénicité des antigènes du vih |
CN110613844B (zh) * | 2019-10-23 | 2024-02-27 | 中国医学科学院生物医学工程研究所 | 一种迷你联合佐剂纳米颗粒及其制备方法和应用 |
CA3161668A1 (fr) | 2019-12-20 | 2021-06-24 | Nammi Therapeutics, Inc. | Compositions liposomales formulees et/ou co-formulees contenant des promedicaments agonistes de recepteurs de type toll (« tlr ») utiles dans le traitement du cancer et methodes a ssociees |
WO2022003443A1 (fr) * | 2020-06-30 | 2022-01-06 | 아이진 주식회사 | Composition d'inhibition de l'hémolyse induite par la saponine, contenant un liposome cationique |
GB2600468A (en) | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
CN112546233A (zh) * | 2020-12-25 | 2021-03-26 | 常州大学 | 一种负载水不溶性免疫调节分子的透明质酸复合材料及其制备方法 |
CN114366810A (zh) * | 2022-02-15 | 2022-04-19 | 中国人民解放军陆军军医大学 | 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用 |
WO2024069420A2 (fr) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Compositions immunogènes comprenant un trimère de protéine f rsv |
CN117771361A (zh) * | 2024-02-27 | 2024-03-29 | 天津中逸安健生物科技有限公司 | 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014454A1 (fr) * | 1992-12-29 | 1994-07-07 | Entremed, Inc. | Vaccins contre les sterols |
US20110206758A1 (en) * | 2005-12-13 | 2011-08-25 | Pierre Vandepapeliere | Vaccine Compositions Comprising a Saponin Adjuvant |
WO2012088414A1 (fr) * | 2010-12-23 | 2012-06-28 | Ludwig Institute For Cancer Research Ltd. | Formulation liposomale de céramides non-glycosidiques et leurs utilisations |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4302459A (en) | 1980-03-19 | 1981-11-24 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
CN1093255A (zh) * | 1986-06-17 | 1994-10-12 | 恩特雷麦德有限公司 | 抗甾醇疫苗 |
IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
US5888519A (en) | 1988-06-02 | 1999-03-30 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections |
US5215680A (en) | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
PL170980B1 (pl) * | 1992-06-25 | 1997-02-28 | Smithkline Beecham Biolog | Szczepionka PL PL PL PL PL PL PL |
GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6846489B1 (en) * | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
JP2001501173A (ja) | 1996-08-23 | 2001-01-30 | アルザ コーポレイション | シスプラチン化合物を含有するリポソーム |
AU4907897A (en) | 1996-10-11 | 1998-05-11 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
NZ336538A (en) | 1996-10-15 | 2001-11-30 | Liposome Co Inc | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
WO2008109398A1 (fr) * | 2007-03-01 | 2008-09-12 | The Catholic University Of America | Bactériophage t4 lié à un substrat |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
-
2015
- 2015-03-25 SG SG11201607396WA patent/SG11201607396WA/en unknown
- 2015-03-25 EP EP15716264.5A patent/EP3122380A1/fr active Pending
- 2015-03-25 KR KR1020167026025A patent/KR102242875B1/ko active IP Right Grant
- 2015-03-25 US US15/127,081 patent/US10434167B2/en active Active
- 2015-03-25 JP JP2017502920A patent/JP6608422B2/ja active Active
- 2015-03-25 SG SG10201808315UA patent/SG10201808315UA/en unknown
- 2015-03-25 CN CN201580026334.9A patent/CN107124869B/zh active Active
- 2015-03-25 CA CA2943190A patent/CA2943190A1/fr not_active Abandoned
- 2015-03-25 RU RU2016141622A patent/RU2016141622A/ru not_active Application Discontinuation
- 2015-03-25 AU AU2015236106A patent/AU2015236106A1/en not_active Abandoned
- 2015-03-25 WO PCT/US2015/022461 patent/WO2015148648A1/fr active Application Filing
- 2015-03-25 MX MX2016012168A patent/MX2016012168A/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014454A1 (fr) * | 1992-12-29 | 1994-07-07 | Entremed, Inc. | Vaccins contre les sterols |
US20110206758A1 (en) * | 2005-12-13 | 2011-08-25 | Pierre Vandepapeliere | Vaccine Compositions Comprising a Saponin Adjuvant |
WO2012088414A1 (fr) * | 2010-12-23 | 2012-06-28 | Ludwig Institute For Cancer Research Ltd. | Formulation liposomale de céramides non-glycosidiques et leurs utilisations |
Non-Patent Citations (3)
Title |
---|
GARCON NATHALIE ET AL: "Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems", EXPERT REVIEW OF VACCINES, EXPERT REVIEWS LTD, GB, vol. 10, no. 4, 1 April 2011 (2011-04-01), pages 471 - 486, XP009176124, ISSN: 1744-8395, DOI: 10.1586/ERV.11.29 * |
See also references of EP3122380A1 * |
ZOLTAN BECK ET AL: "Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, vol. 1848, no. 3, 1 March 2015 (2015-03-01), pages 775 - 780, XP055194486, ISSN: 0005-2736, DOI: 10.1016/j.bbamem.2014.12.005 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017153993A1 (fr) * | 2016-03-09 | 2017-09-14 | Technion Research And Development Foundation Ltd. | Formulations liposomales et leurs procédés d'utilisation en agriculture |
IL261655A (en) * | 2016-03-09 | 2018-10-31 | Technion Res & Development Found Ltd | Liposomal compositions and their uses in agriculture |
CN109152361A (zh) * | 2016-03-09 | 2019-01-04 | 技术研究及发展基金有限公司 | 脂质体制剂及在农业中使用该脂质体制剂的方法 |
EP3615005A4 (fr) * | 2017-04-28 | 2021-03-10 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Compositions et méthodes d'administration de vaccins |
US11583578B2 (en) | 2017-04-28 | 2023-02-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery |
WO2019051149A1 (fr) * | 2017-09-08 | 2019-03-14 | Infectious Disease Research Institute | Formulations liposomales comprenant de la saponine et procédés d'utilisation |
WO2023175454A1 (fr) | 2022-03-14 | 2023-09-21 | Pfizer Inc. | Procédés de production d'adjuvant |
Also Published As
Publication number | Publication date |
---|---|
AU2015236106A1 (en) | 2016-10-20 |
RU2016141622A3 (fr) | 2018-10-26 |
SG11201607396WA (en) | 2016-10-28 |
US10434167B2 (en) | 2019-10-08 |
EP3122380A1 (fr) | 2017-02-01 |
RU2016141622A (ru) | 2018-04-25 |
SG10201808315UA (en) | 2018-10-30 |
JP2017515889A (ja) | 2017-06-15 |
CN107124869B (zh) | 2022-04-01 |
KR20170007242A (ko) | 2017-01-18 |
MX2016012168A (es) | 2017-04-25 |
US20170182152A1 (en) | 2017-06-29 |
CA2943190A1 (fr) | 2015-10-01 |
JP6608422B2 (ja) | 2019-11-20 |
CN107124869A (zh) | 2017-09-01 |
KR102242875B1 (ko) | 2021-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10434167B2 (en) | Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin | |
Beck et al. | Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21 | |
De Serrano et al. | Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines | |
Chatzikleanthous et al. | Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines | |
EP0626169B1 (fr) | Forme de dosage comprenant un antigène et un sel d'un dérivé organoacide d'un stérol | |
Gregoriadis | Immunological adjuvants: a role for liposomes | |
Beck et al. | Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex | |
JP2828391B2 (ja) | オリゴ糖を表面に有するリポソーム | |
US5026557A (en) | Adjuvant composition | |
KR20190025822A (ko) | 페길화된 리포솜 및 이의 용도 | |
US10588963B2 (en) | Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby | |
US6117449A (en) | Method for inducing a systemic immune response to a hepatitis antigen | |
EA024074B1 (ru) | Водная адъювантная композиция, содержащая неионный агент, обеспечивающий изотоничность, иммуногенная композиция и набор на её основе и способ приготовления иммуногенной композиции | |
WO1993017702A1 (fr) | Vaccin oral | |
KR20140130664A (ko) | 외피 바이러스에 의해 야기되는 질병의 치료를 위한 시알로어드히신의 억제제들 | |
US10695424B2 (en) | Method of making a liposome composition | |
US20170165358A1 (en) | Methods for enhancing the immunostimulation potency of aluminum salt-absorbed vaccines | |
JPH05339169A (ja) | 経口ワクチン | |
WO1990001948A1 (fr) | Vaccin contre la grippe et nouveaux adjuvants | |
Gregoriadis | mmunoiogical adjuvants: a role for | |
WO1999000142A1 (fr) | Methode pour provoquer une reponse immunitaire systemique a un antigene de l'hepatite ou du vih |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15716264 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015716264 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015716264 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2943190 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15127081 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/012168 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20167026025 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017502920 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015236106 Country of ref document: AU Date of ref document: 20150325 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016141622 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016021644 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112016021644 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160921 |